23:22 , Mar 28, 2019 |  BioCentury  |  Finance

Polyneuron’s surgical strike

Polyneuron’s broad platform and method of directly targeting autoantibodies rather than B cells for autoimmune diseases prompted Sofinnova Partners and New Enterprise Associates to invest in the Basel-based company’s CHF22.5 million ($22.6 million) series A...
08:18 , Mar 28, 2019 |  BC Extra  |  Financial News

Polyneuron raises $22.6M series A to bring neuropathy therapy into clinic

Backed by Sofinnova Partners and New Enterprise Associates, Polyneuron raised CHF22.5M ($22.6 million) in a series A round to bring its anti-MAG neuropathy therapy, PN-1007, into the clinic. Polyneuron Pharmaceuticals AG (Basel, Switzerland) is developing...
12:44 , Mar 21, 2019 |  BC Innovations  |  Emerging Company Profile

A Passage to optimal CNS vectors

Passage is arming itself with AAV vectors, gene therapies and non-human primate studies from gene therapy pioneer James Wilson at UPenn to develop disease-modifying treatments for rare monogenic diseases affecting the CNS. The company launched...
18:38 , Feb 15, 2019 |  BC Week In Review  |  Financial News

Passage Bio debuts with $115.5M for CNS gene therapies

Co-founded by gene therapy pioneer James Wilson, Passage Bio Inc. (Philadelphia, Pa.) launched with $115.5 million in series A funding Feb 14. Passage is developing five adeno-associated viral gene therapies to treat rare monogenic CNS...
22:54 , Feb 14, 2019 |  BC Extra  |  Financial News

Passage Bio debuts with $115.5M for CNS gene therapies

Co-founded by gene therapy pioneer James Wilson, Passage Bio Inc. (Philadelphia, Pa.) launched with $115.5 million in series A funding Thursday. Passage is developing five adeno-associated viral gene therapies to treat rare monogenic CNS diseases...
19:29 , Dec 21, 2018 |  BC Week In Review  |  Company News

Axovant gets rights to gene therapies from UMass medical school

The University of Massachusetts Medical School (Worcester, Mass.) granted Axovant exclusive, worldwide rights to develop and commercialize two gene therapies to treat GM1 and GM2 gangliosidoses. The school received $10 million up front and is...
18:40 , Aug 8, 2018 |  BC Innovations  |  Emerging Company Profile

Catching antibodies with polymers

Polyneuron Pharmaceuticals AG's glycopolymers act as decoys for the autoantibodies that drive autoimmune diseases, such as anti-MAG neuropathy, and are designed to be more effective and safer than other therapies. Polyneuron's Antibody-Catch platform generates glycopolymers...
19:22 , Jul 28, 2017 |  BioCentury  |  Regulation

Ganging up in rare disease

A joint proposal from EMA and FDA that encourages companies to join multidrug platform trials for pediatric Gaucher’s disease came too late to serve its original purpose. But the proposal could provide a template for...
19:59 , Apr 11, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Animal models LMP1 / LMP2 -overexpressing mice depleted of T cells and NKT cells could be used to screen therapies for EBV-positive lymphoproliferative disease. Mice with germinal center B cell-specific overexpression of LMP1 and...
23:06 , Feb 8, 2017 |  BC Extra  |  Financial News

Lysogene raises EUR 22.6M in IPO

Lysogene S.A. (Euronext:LYS) raised EUR 22.6 million ($24.3 million) through the sale of 3.3 million shares at EUR 6.80 in an IPO underwritten by Societe General and Gilbert Dupont. The offering values the company at...